This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 49/4/792    most recent 01.HYP.0000259737.43916.42v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strazzullo, P. Articles by Cappuccio, F. P. Search for Related Content PubMed PubMed Citation Articles by Strazzullo, P. Articles by Cappuccio, F. P. Related Collections Cardiovascular Pharmacology Primary prevention Clinical Studies Other Treatment

(Hypertension. 2007;49:792.)
© 2007 American Heart Association, Inc.

Original Articles

Do Statins Reduce Blood Pressure?

A Meta-Analysis of Randomized, Controlled Trials

Pasquale Strazzullo; Sally M. Kerry; Antonio Barbato; Marco Versiero; Lanfranco D’Elia; Francesco P. Cappuccio

From the Department of Clinical and Experimental Medicine (P.S., A.B., M.V., L.D.), Federico II University Medical School, Naples, Italy; the Division of Community Health Sciences (S.M.K.), St George’s, University of London, London, United Kingdom; and the Clinical Sciences Research Institute (F.P.C.), Warwick Medical School, Coventry, United Kingdom.

Correspondence to Pasquale Strazzullo, Department of Clinical and Experimental Medicine, "Federico II" University of Naples Medical School, Via S. Pansini, 5, 80131 Naples, Italy. E-mail strazzul{at}unina.it

A meta-analysis was performed of the effect of 3hydroxy3methylglutaryl-coenzyme A reductase inhibitors (statins) on blood pressure in humans including the randomized, controlled trials of statin therapy (20 trials and 828 patients) in which concomitant antihypertensive treatment (if any) remained unchanged throughout the study. A total of 291 and 272 patients were given a statin or placebo, respectively, in parallel group trials, whereas 265 took part in crossover trials receiving a statin and placebo (or probucol, in 1 trial). Systolic blood pressure was significantly lower in patients on statin than in those on placebo or control hypolipidemic drug (mean difference: –1.9 mm Hg; 95% CI: –3.8 to –0.1). The effect was greater when the analysis was restricted to studies with a baseline systolic blood pressure >130 mm Hg ( systolic blood pressure: –4.0; 95% CI: –5.8 to –2.2 mm Hg). There was a trend for lower diastolic blood pressure in patients receiving statin therapy compared with control: –0.9 mm Hg (95% CI: –2.0 to 0.2) overall and –1.2 mm Hg (95% CI: –2.6 to 0.1) in studies with a baseline diastolic blood pressure >80 mm Hg. In general, the higher the baseline blood pressure, the greater the effect of statins on blood pressure (P=0.066 for systolic blood pressure and P=0.023 for diastolic blood pressure). The blood pressure response to statins was unrelated to age, changes in serum cholesterol, or length of the trial. In conclusion, statin therapy has a relatively small but statistically significant and clinically meaningful effect on blood pressure.

Key Words: blood pressure • hypertension, arterial • hypercholesterolemia • drug therapy • statins • meta-analysis

This article has been cited by other articles:

				C. Manisty, J. Mayet, R. J. Tapp, P. S. Sever, N. Poulter, S. A. McG. Thom, A. D. Hughes, and on behalf of the ASCOT Investigators Atorvastatin Treatment Is Associated With Less Augmentation of the Carotid Pressure Waveform in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) Hypertension, November 1, 2009; 54(5): 1009 - 1013. [Abstract] [Full Text] [PDF]

				V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, J. R. Sowers, B. T. Andresen, A. A. Gutweiler, L. Ma, M. S. Johnson, C. M. Ferrario, et al. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H1128 - H1139. [Abstract] [Full Text] [PDF]

				P. C. Lavallee, J. Labreuche, F. Gongora-Rivera, A. Jaramillo, D. Brenner, I. F Klein, P.-J. Touboul, E. Vicaut, P. Amarenco, and on behalf of the Lacunar-B.I.C.H.A.T. Investigator Placebo-Controlled Trial of High-Dose Atorvastatin in Patients With Severe Cerebral Small Vessel Disease Stroke, May 1, 2009; 40(5): 1721 - 1728. [Abstract] [Full Text] [PDF]

				M. E. Safar, A. D. Protogerou, and J. Blacher Statins, Central Blood Pressure, and Blood Pressure Amplification Circulation, January 6, 2009; 119(1): 9 - 12. [Full Text] [PDF]

				B. Williams, P. S. Lacy, J. K. Cruickshank, D. Collier, A. D. Hughes, A. Stanton, S. Thom, H. Thurston, and for the CAFE and ASCOT Investigators Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics: Principal Results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study Circulation, January 6, 2009; 119(1): 53 - 61. [Abstract] [Full Text] [PDF]

				R. Muniyappa, G. Hall, T. L Kolodziej, R. J Karne, S. K Crandon, and M. J Quon Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension Am. J. Clinical Nutrition, December 1, 2008; 88(6): 1685 - 1696. [Abstract] [Full Text] [PDF]

				D. E. Laaksonen, L. Niskanen, K. Nyyssonen, T. A. Lakka, J. A. Laukkanen, and J. T. Salonen Dyslipidaemia as a predictor of hypertension in middle-aged men Eur. Heart J., October 2, 2008; 29(20): 2561 - 2568. [Abstract] [Full Text] [PDF]

				B. Williams The Year in Hypertension J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1803 - 1817. [Full Text] [PDF]

				B. A. Golomb, J. E. Dimsdale, H. L. White, J. B. Ritchie, and M. H. Criqui Reduction in Blood Pressure With Statins: Results From the UCSD Statin Study, a Randomized Trial Arch Intern Med, April 14, 2008; 168(7): 721 - 727. [Abstract] [Full Text] [PDF]

				P. M. Ho, D. J. Magid, S. M. Shetterly, K. L. Olson, P. N. Peterson, F. A. Masoudi, and J. S. Rumsfeld Importance of Therapy Intensification and Medication Nonadherence for Blood Pressure Control in Patients With Coronary Disease Arch Intern Med, February 11, 2008; 168(3): 271 - 276. [Abstract] [Full Text] [PDF]

				P. Korantzopoulos, M. Elisaf, and H. J. Milionis Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease ready for prime time? Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2768 - 2774. [Full Text] [PDF]

				K. K. Koh Combination Treatment to Prevent Atherosclerosis Hypertension, September 1, 2007; 50(3): e67 - e67. [Full Text] [PDF]

				P. Strazzullo and L. D'Elia Response to Combination Treatment to Prevent Atherosclerosis Hypertension, September 1, 2007; 50(3): e68 - e68. [Full Text] [PDF]

				From the Library Br J Ophthalmol, August 1, 2007; 91(8): 1098 - 1098. [Full Text] [PDF]

				E. Cereda and A. Pietrobelli Statins and Blood Pressure Lowering: A Claim for Ad-Hoc Trials Hypertension, August 1, 2007; 50(2): e12 - e12. [Full Text] [PDF]

				P. Strazzullo and A. Barbato Response to Statins and Blood Pressure Lowering: A Claim for Ad-Hoc Trials Hypertension, August 1, 2007; 50(2): e13 - e13. [Full Text] [PDF]

				M.-S. Zhou Upregulation of Nitric Oxide, Inhibition of Oxidative Stress, and Antihypertensive Effects of Statins Hypertension, June 1, 2007; 49(6): e43 - e43. [Full Text] [PDF]

				P. Strazzullo, L. D'Elia, and M. Versiero Response to Upregulation of Nitric Oxide, Inhibition of Oxidative Stress, and Antihypertensive Effects of Statins Hypertension, June 1, 2007; 49(6): e44 - e44. [Full Text] [PDF]